Veronica Ashton

970 total citations
64 papers, 665 citations indexed

About

Veronica Ashton is a scholar working on Cardiology and Cardiovascular Medicine, Internal Medicine and Economics and Econometrics. According to data from OpenAlex, Veronica Ashton has authored 64 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Cardiology and Cardiovascular Medicine, 31 papers in Internal Medicine and 16 papers in Economics and Econometrics. Recurrent topics in Veronica Ashton's work include Atrial Fibrillation Management and Outcomes (44 papers), Venous Thromboembolism Diagnosis and Management (31 papers) and Health Systems, Economic Evaluations, Quality of Life (15 papers). Veronica Ashton is often cited by papers focused on Atrial Fibrillation Management and Outcomes (44 papers), Venous Thromboembolism Diagnosis and Management (31 papers) and Health Systems, Economic Evaluations, Quality of Life (15 papers). Veronica Ashton collaborates with scholars based in United States, Canada and Germany. Veronica Ashton's co-authors include Eric D. Peterson, Kenneth Todd Moore, Alex C. Spyropoulos, Bingcao Wu, Craig I Coleman, Patrick Lefèbvre, François Laliberté, Anselm K. Gitt, Dominik Lautsch and Baishali Ambegaonkar and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Journal of the American College of Cardiology.

In The Last Decade

Veronica Ashton

57 papers receiving 650 citations

Peers

Countries citing papers authored by Veronica Ashton

Since Specialization

Citations

This map shows the geographic impact of Veronica Ashton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veronica Ashton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veronica Ashton more than expected).

Fields of papers citing papers by Veronica Ashton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veronica Ashton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veronica Ashton. The network helps show where Veronica Ashton may publish in the future.

Co-authorship network of co-authors of Veronica Ashton

This figure shows the co-authorship network connecting the top 25 collaborators of Veronica Ashton. A scholar is included among the top collaborators of Veronica Ashton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veronica Ashton. Veronica Ashton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Health Care Resource Use and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Polypharmacy Patients With Obesity 2025 ·Journal of the American Heart Association ·Mark J. Alberts, Jinghua He, (unknown), Christopher D. Pericone, Veronica Ashton	0
2	Out-of-pocket costs for direct oral anticoagulants and prescription abandonment among patients with nonvalvular atrial fibrillation or venous thromboembolism 2025 ·Journal of Managed Care & Specialty Pharmacy ·Maryia Zhdanava, Veronica Ashton, Jill Korsiak, (unknown), Dominic Pilon, Mark J. Alberts	0
3	Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease 2024 ·American Journal of Hypertension ·George L. Bakris, Cindy Chen, (unknown), Veronica Ashton, Lloyd Haskell, (unknown)	0
4	Non-Medical Switching or Discontinuation Patterns among Patients with Non-Valvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States: A Claims-Based Analysis 2024 ·SHILAP Revista de lepidopterología ·M. Ingham, (unknown), Aarti A. Patel, Veronica Ashton, (unknown), (unknown), Patrick Lefèbvre, Marie‐Hélène Lafeuille	0
5	Association of uncontrolled blood pressure in apparent treatment‐resistant hypertension with increased risk of major adverse cardiovascular events plus 2023 ·Journal of Clinical Hypertension ·George L. Bakris, Cindy Chen, (unknown), Veronica Ashton, Lloyd Haskell, (unknown)	6
6	Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States 2022 ·Journal of Thrombosis and Thrombolysis ·Jeffrey S. Berger, François Laliberté, (unknown), Dominique Lejeune, Kenneth Todd Moore, Young Yun Jung, Patrick Lefèbvre, Veronica Ashton	6
7	Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States 2022 ·Clinical and Applied Thrombosis/Hemostasis ·W. Frank Peacock, James M. Crawford, Yen‐Wen Chen, Veronica Ashton, (unknown), Dejan Milentijevic, Alex C. Spyropoulos	5
8	Occurrence of Thromboembolic Events and Mortality Among Hospitalized Coronavirus 2019 Patients: Large Observational Cohort Study of Electronic Health Records 2022 ·SHILAP Revista de lepidopterología ·Alex C. Spyropoulos, James M. Crawford, Yen‐Wen Chen, Veronica Ashton, (unknown), Dejan Milentijevic, W. Frank Peacock	6
9	Comparative Effectiveness and Safety of Rivaroxaban and Warfarin Among Nonvalvular Atrial Fibrillation (NVAF) Patients with Obesity and Polypharmacy in the United States (US) 2021 ·Advances in Therapy ·Jeffrey S. Berger, François Laliberté, (unknown), Dominique Lejeune, Kenneth Todd Moore, Young Yun Jung, Patrick Lefèbvre, Veronica Ashton	5
10	The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations 2021 ·The Journal of Clinical Pharmacology ·Veronica Ashton, (unknown), Kenneth Todd Moore	13
11	Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy 2021 ·Journal of Comparative Effectiveness Research ·François Laliberté, Veronica Ashton, (unknown), Dominique Lejeune, Kenneth Todd Moore, Young Yun Jung, Patrick Lefèbvre, Jeffrey S. Berger	3
12	Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population 2021 ·Current Medical Research and Opinion ·Jeffrey S. Berger, François Laliberté, (unknown), Dominique Lejeune, Kenneth Todd Moore, Young Yun Jung, Patrick Lefèbvre, Veronica Ashton	16
13	Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population 2021 ·Journal of Medical Economics ·Jeffrey S. Berger, François Laliberté, (unknown), Dominique Lejeune, Kenneth Todd Moore, Young Yun Jung, Patrick Lefèbvre, Veronica Ashton	5
14	Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data 2020 ·Current Medical Research and Opinion ·(unknown), Jan Beyer‐Westendorf, Veronica Ashton, Dejan Milentijevic, Kenneth Todd Moore, Thomas J. Bunz, Craig I Coleman	30
15	The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations 2020 ·American Journal of Cardiovascular Drugs ·Veronica Ashton, (unknown), Kenneth Todd Moore	10
16	RIVAROXABAN VERSUS WARFARIN IN AFRICAN AMERICAN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION 2020 ·Journal of the American College of Cardiology ·Craig I Coleman, (unknown), Veronica Ashton, Michael A. Palladino, Thomas J. Bunz	2
17	Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world 2017 ·Data in Brief ·Anselm K. Gitt, Dominik Lautsch, Jean Ferrières, Gaetano Maria De Ferrari, Ami Vyas, Carl A. Baxter, Lori D. Bash, Veronica Ashton, Martin Horack, Wael Almahmeed, Fu‐Tien Chiang, Kian Keong Poh, Philippe Brudi, Baishali Ambegaonkar	5
18	Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study 2017 ·Archives of cardiovascular diseases ·Jean Ferrières, (unknown), Dominik Lautsch, Veronica Ashton, Baishali Ambegaonkar, Philippe Brudi, Anselm K. Gitt	17
19	0186: Are coronary patients on lipid-lowering therapy in Europe achieving the recommended LDL-C target? Results from the Dyslipidemia International Study (DYSIS) II Europe 2016 ·Archives of Cardiovascular Diseases Supplements ·Anselm K. Gitt, Jean Ferrières, Gaetano Maria De Ferrari, Moses Elisaf, Michel P. Hermans, Thomas J. Kiernan, Р. Г. Оганов, (unknown), Dominik Lautsch, Veronica Ashton, Baishali Ambegaonkar	0
20	Prevalence of lipid abnormalities among treated patients with stable CHD: The Dyslipidemia International Study (DYSIS) II South Korea results 2015 ·Atherosclerosis ·(unknown), (unknown), Myung Ho Jeong, (unknown), Woong Chol Kang, Seung‐Ho Hur, Dong Woon Jeon, (unknown), (unknown), Jin‐Ok Jeong, (unknown), Hyeon‐Cheol Gwon, Kook Jin Chun, (unknown), (unknown), Ki‐Bae Seung, Y.H. Kim, Anselm K. Gitt, Veronica Ashton, (unknown), (unknown), Yangsoo Jang	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact